The glioblastoma resistance to various therapies is mainly due to an extremely mutated genome and over-activation of tyrosine kinase receptors, such as EGFR, PDGFR and VEGFR, which are usually up-regulated in glioblastoma [100,101,102,103]. The gene discussed is PDGFRB; the disease is glioblastoma.